A Phase 3, randomized, placebo-controlled, 12-week, double-blind study, plus a non-controlled extension treatment period, to assess efficacy and safety of fezolinetant, a neurokin-3 receptor antagonist, in women with moderate-to-severe vasomotor symptoms associated with menopause

被引：0

作者：

Johnson, Kimball ^{[1
]}

Lademacher, Christopher ^{[3
]}

Nappi, Rossella E. ^{[8
]}

Neal-Perry, Genevieve ^{[4
]}

Shapiro, Marla ^{[5
]}

Stute, Petra ^{[6
]}

Thurston, Rebecca C. ^{[7
]}

Wolfman, Wendy ^{[5
]}

English, Marci ^{[3
]}

Franklin, Catherine ^{[3
]}

Lee, Misun ^{[3
]}

Santoro, Nanette ^{[2
]}

机构：

[1] iRes Atlanta LLC, Decatur, GA USA

[2] CU, Sch Med, Aurora, CO USA

[3] Astellas Pharma Global Dev Inc, Northbrook, IL USA

[4] UNC, Sch Med, Chapel Hill, NC USA

[5] Univ Toronto, Toronto, ON, Canada

[6] Univ Spital Bern, Inselspital, Bern, Switzerland

[7] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[8] Univ Pavia, IRCCS S Matteo, Pavia, Italy

来源：

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2021年 / 28卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

S-13

引用

页码：1450 / 1450

页数：1